Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kindred Biosciences (KIN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 367,245
  • Shares Outstanding, K 33,913
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,880 K
  • 36-Month Beta 0.65
  • Price/Sales 573.82
  • Price/Cash Flow N/A
  • Price/Book 3.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.42
  • Number of Estimates 2
  • High Estimate -0.40
  • Low Estimate -0.43
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.55 +13.40%
on 02/01/19
11.28 -3.99%
on 01/16/19
-0.34 (-3.04%)
since 01/15/19
3-Month
9.55 +13.40%
on 02/01/19
13.96 -22.42%
on 11/29/18
-1.83 (-14.45%)
since 11/15/18
52-Week
8.05 +34.53%
on 03/28/18
15.75 -31.24%
on 08/13/18
+2.28 (+26.67%)
since 02/15/18

Most Recent Stories

More News
Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal...

KIN : 10.83 (+3.44%)
Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares...

KIN : 10.83 (+3.44%)
Kindred Biosciences Named Best Company in North America by Leading Industry Publication

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America...

KIN : 10.83 (+3.44%)
Kindred Biosciences Announces Pricing of Public Offering

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of...

KIN : 10.83 (+3.44%)
Kindred Biosciences Announces Proposed Public Offering of Common Stock

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock....

KIN : 10.83 (+3.44%)
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat(TM) for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness...

KIN : 10.83 (+3.44%)
Recent Analysis Shows Spirit Airlines, Cactus, Evergy, ADDvantage Technologies Group, Kindred Biosciences, and Farfetch Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spirit Airlines, Inc. (NYSE:SAVE),...

KIN : 10.83 (+3.44%)
WHD : 36.60 (+2.52%)
FTCH : 19.60 (+3.16%)
AEY : 1.38 (unch)
EVRG : 58.77 (+0.60%)
SAVE : 61.67 (+0.41%)
Kindred Bio: 3Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Wednesday reported a loss of $13 million in its third quarter.

KIN : 10.83 (+3.44%)
Kindred Biosciences Announces Third Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September...

KIN : 10.83 (+3.44%)
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies

Financialnewsmedia.com News Commentary

KIN : 10.83 (+3.44%)
ARRY : 23.13 (+4.95%)
SBBP : 4.74 (+0.85%)
PFE : 42.40 (+1.02%)
MBRX : 1.47 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade KIN with:

Business Summary

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have...

See More

Key Turning Points

2nd Resistance Point 11.15
1st Resistance Point 10.99
Last Price 10.83
1st Support Level 10.59
2nd Support Level 10.34

See More

52-Week High 15.75
Fibonacci 61.8% 12.81
Fibonacci 50% 11.90
Fibonacci 38.2% 10.99
Last Price 10.83
52-Week Low 8.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar